Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Sees Large Increase in Short Interest

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 10,600 shares, a growth of 15.2% from the March 31st total of 9,200 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily volume of 42,800 shares, the days-to-cover ratio is presently 0.2 days.

Hedge Funds Weigh In On Finch Therapeutics Group

A hedge fund recently bought a new stake in Finch Therapeutics Group stock. MSD Partners L.P. acquired a new stake in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,113 shares of the company’s stock, valued at approximately $26,000. MSD Partners L.P. owned about 0.32% of Finch Therapeutics Group as of its most recent filing with the Securities and Exchange Commission (SEC). 21.77% of the stock is owned by institutional investors.

Finch Therapeutics Group Price Performance

Shares of FNCH traded down $0.02 during mid-day trading on Monday, hitting $2.30. 39,285 shares of the company traded hands, compared to its average volume of 38,102. Finch Therapeutics Group has a one year low of $1.86 and a one year high of $16.74. The business has a 50-day moving average of $2.53 and a 200 day moving average of $3.14.

Finch Therapeutics Group (NASDAQ:FNCH) last released its quarterly earnings results on Monday, March 25th. The company reported ($1.89) EPS for the quarter.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.